Articles by Nicholas Jacobus

In today’s Pharmaceutical Executive Daily, we cover major leadership changes at Novo Nordisk, Kenvue’s request for the FDA to reject a petition calling for Tylenol label changes, and industry insights from Bob Mauch on building a stronger, more resilient pharmaceutical supply chain.

Novo Nordisk faces significant board changes and stock declines as it navigates governance conflicts with its foundation, aiming for future growth.

Recent research shows mRNA COVID vaccines significantly enhance survival rates in cancer patients undergoing immunotherapy, potentially revolutionizing cancer treatment.

The collaboration will focus on enhancing cancer therapies through next-gen immuno-oncology and ADC treatments for solid tumors.

Peptilogics Founder and CEO, Jonathan Steckbeck, explained that PLG0206’s membrane-active mechanism enables it to destroy both active and dormant biofilm bacteria overcoming a key limitation of traditional antibiotics.

In today’s Pharmaceutical Executive Daily, we cover Merck’s $70 billion expansion of U.S. operations, the FDA’s latest approvals for Novo Nordisk’s Rybelsus and Roche’s Gazyva, and a new digital health partnership between Amazon and WeightWatchers bringing prescription weight-loss drugs directly to consumers.

Galapagos scales back its cell therapy business to enhance efficiency and focus on transformative opportunities, impacting over 365 employees globally.

Sanofi's Tzield gains FDA's expedited review, promising rapid access to innovative treatment for type 1 diabetes and addressing significant medical needs.

Peptilogics Founder and CEO, Jonathan Steckbeck noted that advances in peptide design and safety have positioned the field to address drug-resistant pathogens more effectively.

In today’s Pharmaceutical Executive Daily, we cover the FDA’s creation of a new National Priority Voucher Program, the market reaction to President Trump’s remarks on GLP-1 drug prices, and how autonomous AI is transforming omnichannel marketing in pharma.

Merck invests $70 billion in US operations, launching a $3 billion manufacturing site in Virginia to enhance drug production and create jobs.

FDA approves innovative treatments for lupus nephritis and cardiovascular risk in diabetes, enhancing chronic disease management options for patients.

In today’s Pharmaceutical Executive Daily, we explore how antibody-drug conjugate collaborations are moving beyond oncology into autoimmune diseases, EMD Serono’s agreement with the Trump administration to expand access to in vitro fertilization therapies, and how the obesity treatment market is evolving after GLP-1 dominance.

Peptilogics Founder, CEO, Jonathan Steckbeck, explained that PLG0206 stands apart from current treatments, while the company’s discovery platform transforms drug development from an iterative search process into a data-driven design model.

EMD Serono partners with the U.S. government to enhance IVF access, offering significant discounts on fertility treatments for millions of women.

Hunter Smith, CFO of Rhythm Pharmaceuticals, emphasized that in rare disease biotech, financial leadership must evolve from strict cost control to strategic partnerships.

In today’s Pharmaceutical Executive Daily, we explore how pharma leaders are rethinking workforce development at the executive level, the industry’s growing investment in rare disease therapies, and emerging opportunities and challenges in psychiatric drug development.

Biopharmaceutical funding surges as companies like Veradermics, Peptilogics, and BridGene advance innovative therapies through significant financing rounds.

Pharmaceutical companies enhance cancer and autoimmune disease treatments through strategic collaborations, advancing innovative therapies, and improving patient outcomes.

In today’s Pharmaceutical Executive Daily, we explore Johnson & Johnson’s plan to separate its orthopedics division into a standalone company, the global implications of the Most Favored Nation drug pricing proposal, and strategies helping small biotechs reach market faster.

Biotech funding surges as companies like Pelage, Kardigan, and Kailera secure millions to innovate treatments for hair loss, obesity, and cardiovascular diseases.

The biopharmaceutical sector sees major acquisitions, enhancing capabilities in RNA therapies and rare diseases, with key players like BioCryst and Bristol Myers Squibb leading the charge.

Hunter Smith,CFO of Rhythm Pharmaceuticals, noted that maintaining balance between investor expectations and long-term biotech priorities depends on partnering.

In today’s Pharmaceutical Executive Daily, we cover Takeda’s new multi-year research collaboration with Nabla Bio, how tariff and pricing pressures are driving pharma toward direct-to-consumer strategies, and reports of AstraZeneca reaching an agreement with the Trump administration.

Johnson & Johnson plans to separate its orthopaedics business, creating DePuy Synthes, to enhance focus, innovation, and value for stakeholders.

Nabla Bio and Takeda enhance their partnership to revolutionize AI-driven protein therapeutics, aiming for groundbreaking advancements in drug development.

Hunter Smith, CFO of Rhythm Pharmaceuticals, explains that in biotech, success often brings greater capital demands before profitability, requiring CFOs to balance continuous fundraising with careful management.

In today’s Pharmaceutical Executive Daily, we cover Ypsomed’s new North Carolina manufacturing site, how pharma leaders are maintaining strategic clarity amid policy whiplash, and Excellergy’s $70 million Series A launch to advance its trifunctional immunotherapy platform.

Pharmaceutical companies embrace direct-to-consumer sales and price cuts amid tariff changes and Trump's push for lower drug costs in the US.

Excellergy secures $70 million to advance innovative trifunctional ECRIs, aiming to redefine allergy treatment and improve patient outcomes.